Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …

Recent studies have focused on treating heart failure, primarily mitigating symptoms and
reducing the risk of mortality and other cardiovascular complications. A promising new …

Abstract Sacubitril/valsartan (SAC/VAL), an angiotensin receptor blocker-neprilysin inhibitor,
has been widely used to treat several types of heart failure. Nevertheless, the effects of …

Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …

Objectives: Arterial hypertension, when exacerbated by excessive dietary salt intake,
worsens the morbidity and mortality rates associated with cardiovascular and renal …

Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and
cardiovascular mortality in a randomized controlled trial. However, little is known about real …

Abstract Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes
in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been …

Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two
well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan …

Background Left ventricular (LV) remodelling is a major mechanism underlying disease
progression in patients with heart failure (HF) with reduced ejection fraction (EF). Previous …